Ketolides Global Market Report 2024

The global ketolides market has grown strongly in recent years. It will grow from $3.07 billion in 2023 to $3.22 billion in 2024 at a compound annual growth rate (CAGR) of 5.0%. The growth in the historic period can be attributed to increasing prevalence of infectious diseases, growing consumption of antibiotics, demand for effective and convenient treatments for infectious diseases, government initiatives.

The global ketolides market is expected to see steady growth in the next few years. It will grow to $3.82 billion in 2028 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to investments in research and development activities for ketolides, growing number of screening programs for infectious diseases, incremental healthcare spending. growing awareness of antimicrobial stewardship. Major trends in the forecast period include innovative treatments for infectious diseases, development of targeted therapies, advancements in diagnosis and treatment of infectious diseases, development of new ketolide formulations.

The escalating prevalence of infectious diseases is anticipated to drive the expansion of the ketolides market in the foreseeable future. Infectious diseases encompass a broad spectrum of illnesses caused by various pathogens, including bacteria, viruses, fungi, or parasites, which can be transmitted from one person to another, resulting in a wide array of symptoms and health complications. Among these diseases, tuberculosis stands out as a significant concern. Ketolides, a class of antibiotics utilized in the treatment of infectious diseases, have garnered attention for their potential in managing tuberculosis due to their effectiveness in intracellular activities, a key factor in combating tuberculosis. For instance, as of October 2022, the World Health Organization's Global Tuberculosis Report revealed a projected 4.5% increase in tuberculosis (TB) cases globally, with an estimated 10.6 million cases in 2021, up from 10.1 million cases in 2020. As such, the surging prevalence of infectious diseases is the driving force behind the growth of the ketolides market.

The ketolides market is witnessing growth, primarily attributed to the increasing prevalence of chronic sinusitis. Chronic sinusitis is characterized by persistent inflammation in the sinus cavities around the nasal passages. Ketolides, a class of antibiotics with immunomodulatory and anti-inflammatory properties, find application in the treatment of various medical conditions. Given that chronic sinusitis involves inflammation of the sinuses, ketolides play a role in mitigating this inflammation and alleviating associated symptoms. For example, data from the US-based Centers for Disease Control and Prevention (CDC) as of January 2022 indicated that approximately 11.6% of adults in the United States had received diagnoses of sinusitis. Consequently, the expanding occurrence of chronic sinusitis serves as a driving force behind the growth of the ketolides market.

Major players in the ketolides market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, GSK PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Shionogi & Company Limited, Dr. Reddys Laboratories Ltd., Taisho Pharmaceutical Co. Ltd., Glenmark Pharmaceuticals Ltd., Zhejiang Yongtai Technology Co. Ltd., Corden Pharma GmbH, Optimer Pharmaceuticals Inc., Vivimed Labs Limited, Wockhardt Ltd., Advanced Life Sciences Holdings Inc.

The growth of the ketolides market faces hindrances due to the side effects associated with the medication. These side effects, which include diarrhea, nausea, vomiting, and dizziness, present significant challenges and are expected to limit market expansion over the projected period. Ketolides, as a class of antibiotics used to combat bacterial infections, exhibit efficacy in eradicating or inhibiting the growth of bacteria. However, they also carry a range of adverse effects on the body. For instance, as of October 2021, according to information provided by RxList, a US-based online medical resource company, diarrhea is a commonly observed side effect of ketolides, such as telithromycin. Clinical trials involving patients with respiratory tract infections reported that telithromycin was associated with diarrhea in approximately 10.8% of cases. Consequently, the hindrance posed by medication side effects is impeding the growth of the ketolides market.

The leading companies within the ketolides market are strongly committed to pioneering innovative drugs and treatment approaches, with the aim of gaining a competitive edge and maintaining their market position. For instance, AliquantumRx Inc., a US-based biotechnical research company, which, in June 2023, celebrated the approval of a patent by the United States Patent and Trademark Office (USPTO), a key agency under the Department of Commerce. This patent, titled 'salts and polymorphs of cethromycin for the treatment of bacterial and protozoan disease,' pertains to cethromycin, a ketolide antibiotic that demonstrates effectiveness against various infectious diseases caused by both bacteria and protozoa. These conditions encompass malaria, babesiosis, toxoplasmosis, diarrhea, and more. Notably, this newly granted patent significantly expands the possibilities for the use of cethromycin, potentially lowering the barriers to its commercialization and facilitating its application in treating a broader range of diseases.

Growth Of The Ketolides Market Is Being Driven By The Expanding Healthcare Industry

North America was the largest region in the ketolides market in 2023. The regions covered in ketolides report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the ketolides market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary drugs falling under the ketolides category include telithromycin, cethromycin, and solithromycin. Telithromycin, a semi-synthetic antibiotic of the ketolide class, is deployed in the treatment of respiratory tract infections. These antibiotics find application in a range of conditions, including bronchitis, pneumonia, sinusitis, tonsillitis, and pharyngitis. They target various microorganisms such as Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Chlamydophila pneumoniae, and Mycoplasma pneumoniae. Ketolides are distributed through diverse channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others.

This report provides ketolides market statistics, including ketolides industry global market size, regional shares, competitors with a ketolides market share, detailed ketolides market segments, market trends and opportunities and any further data you may need to thrive in the ketolides industry. This ketolides market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ketolides market consists of sales of solithera and ketek, arylalkyl and macrolactone rings. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.